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ABSTRACT
RIG-I and MDA5 sense cytoplasmic viral RNA and
set-off a signal transduction cascade, leading to
antiviral innate immune response. The third RIG-I-
like receptor, LGP2, differentially regulates RIG-I-
and MDA5-dependent RNA sensing in an unknown
manner. All three receptors possess a C-terminal
regulatory domain (RD), which in the case of RIG-I
senses the viral pattern 5’-triphosphate RNA and
activates ATP-dependent signaling by RIG-I. Here
we report the 2.6A ˚ crystal structure of LGP2
RD along with in vitro and in vivo functional analyses
and a homology model of MDA5 RD. Although LGP2
RD is structurally related to RIG-I RD, we find it
rather binds double-stranded RNA (dsRNA) and
this binding is independent of 5’-triphosphates.
We identify conserved and receptor-specific parts
of the RNA binding site. Latter are required for spe-
cific dsRNA binding by LGP2 RD and could confer
pattern selectivity between RIG-I-like receptors. Our
data furthermore suggest that LGP2 RD modulates
RIG-I-dependent signaling via competition for
dsRNA, another pattern sensed by RIG-I, while a
fully functional LGP2 is required to augment
MDA5-dependent signaling.
INTRODUCTION
Upon pathogen infection the mammalian innate immune
system represents the ﬁrst line of defense. The response to
pathogens by the innate immune system of mammals is
initiated by the detection of pathogen-associated molecu-
lar patterns (PAMPs) by host pattern recognition
receptors (1,2). Viral RNA is recognized in the endosome
by membrane-bound Toll-like receptors (3), or in the
cytoplasm by DExH box ATPases RIG-I (retinoic acid-
inducible gene 1), MDA5 (melanoma diﬀerentiation-
associated antigen 5) and LGP2 (laboratory of genetics
and physiology 2) (4–6). RIG-I is a sensor for e.g. hepatitis
C virus (7), Sendai virus (8), vesicular stomatitis virus (9),
rabies virus (10), inﬂuenza virus and Japanese encephalitis
virus (11), while MDA5 appears to detect picornaviruses
and noroviruses (11,12). Overlapping roles of RIG-I and
MDA5 were demonstrated for reovirus and dengue virus
(13). LGP2 has not been shown yet to directly signal upon
interaction with viral RNA but appears to have a regula-
tory role in virus sensing (6,14,15).
Upon recognition of cytosolic viral RNA, RIG-I and
MDA5 bind to the adaptor protein MAVS (also known as
CARDIF, IPS-1 or VISA), which is located in the outer
mitochondrial membrane (9,16–18). The interaction
of RIG-I or MDA5 with MAVS is mediated by two
N-terminal caspase activation and recruitment domains
(CARDs) of RIG-I and MDA5 (19,20) and initiates
downstream signaling, resulting in an antiviral response
by interferon a/b production and activation of interferon
stimulated genes as well as NFkB target genes (21).
While the PAMPs for MDA5 are unclear, RIG-I senses
50-triphosphates on viral RNAs (10,22,23), modiﬁcations
that arise from RNA synthesis by many viruses, but are
typically not found on normally capped, dephosphory-
lated or processed cellular RNA molecules. RIG-I also
recognizes poly-U/UC rich regions in the HCV genome
(24), 30- and 50-monophosphates of double-stranded
RNA (dsRNA) (25) as well as RNA molecules generated
by the activity of the antiviral 20-50 oligoadenylate-
activated RNase L on host RNA molecules (26). The pre-
cise mechanism of PAMP sensing by RIG-I is still
unclear. A C-terminal regulatory domain (RD) that is a
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(25,27). The DExH box ATPase domain of RIG-I is acti-
vated by dsRNA in vitro and may participate in dsRNA
sensing (28,29). Current models suggest that PAMP bind-
ing results in RIG-I dimerization and together with ATP
perhaps induces a conformation that leads to initiation of
downstream events (27,30). The recognition of PAMPs
and the initiation and time course of the antiviral response
is highly regulated and involves RIG-I ubiquitinylation
(31,32) as well as several positive and negative regulatory
factors (33).
A poorly understood putative regulator of antiviral
response is the third identiﬁed member of the RIG-I-like
ATPase family, LGP2. LGP2 diﬀers from RIG-I and
MDA5 by the lack of the two N-terminal CARDs but
shares the DExH box ATPase domain and a C-terminal
RD. The exact function of LGP2 is controversial. It has
been shown to inhibit RIG-I signaling and activity both
in vivo and in vitro (6,14,15,34). However, it has been indi-
cated that MDA5 signaling is stimulated in the presence of
LGP2 (35). Additionally there is evidence that despite
lacking the N-terminal CARDs LGP2 can interact with
IPS-1, thereby competing with the downstream kinase
IKKi/e and inhibiting activation of transcription factor
IRF-3 (interferon regulatory factor 3) (15).
Upon dsRNA binding LGP2 also forms dimers, sug-
gesting an activation mechanism related to RIG-I (34).
In support of this, the C-terminal RDs of all three RIG-
I-like ATPases share sequence elements, in particular four
invariant cysteine residues. The RD of RIG-I was found
to be structurally related to GDP/GTP exchange factors
of Rab-like small GTPases (36) and contains a zinc-bind-
ing site, formed by the four invariant cysteines, as a
prominent feature. However many residues, shown to be
crucial for 50-triphosphate-dependent binding of RNA in
RIG-I RD, vary amongst the other two representatives
and may confer selectivity towards diﬀerent RNA mole-
cules (27).
To learn more about structure and function of the reg-
ulatory domains of RIG-I-like receptors, we determined
the crystal structure of the RD of LGP2 as well as a solu-
tion structure of MDA5 RD, determined by small angle
X-ray scattering. The crystal structure of human LGP2
RD revealed a zinc-binding site and the overall structure
shares fold with RIG-I RD. However, we tested RNA
binding selectivity of LGP2 RD and found a strong pref-
erence for dsRNA over single-stranded RNA (ssRNA),
while 50-triphosphates had no signiﬁcant eﬀect on RNA
binding. This is a marked diﬀerence to RIG-I RD and
argues that RDs are indeed pattern sensor sites. Using
site-directed mutants, we derive commonalities and diﬀer-
ences between RIG-I and LGP2 RDs. Our data suggest
that RDs of RIG-I, LGP2 and possibly MDA5 share a
common RNA binding site at the center of a concave
surface, while a peripheral pocket and loop might confer
speciﬁcity towards distinct patterns. Finally, in vivo ana-
lysis suggests that RD as well as DExH box domain can
individually inhibit RIG-I-dependent signaling, but an
intact LGP2 is necessary to augment MDA5-dependent
signaling.
MATERIALS AND METHODS
Proteinproduction andpurification
RDs of human LGP2 (residues 537–678, native C-
terminus) were expressed in Escherichia coli Rosetta
DE3 cells using a pET21a expression vector (Novagen).
Cells were grown in shaking culture in Luria Bertani broth
to an OD600 of 0.8at 378C. Protein production was started
by the addition of 0.13mM isopropyl-beta-D-thiogalacto-
pyranoside (IPTG) and the cells were shaken over night at
188C. After harvest by centrifugation, cells were resus-
pended in lysis buﬀer (30mM Tris–HCl pH 7.0, 100mM
NaCl, 2mM dithiothreitol (DTT) and 10mM ZnCl2) and
disrupted by soniﬁcation. Proteins were puriﬁed using
HiTrapSP cation exchange chromatography and
Superdex S75 gel ﬁltration, according to standard proto-
cols (GE Healthcare). The puriﬁed protein [in 30mM
Tris–HCl pH 7.5, 150mM NaCl, 2mM DTT, 10mM
ZnCl2 and 5% (v/v) glycerol] was concentrated to 5–15
mg/ml, ﬂash frozen in liquid nitrogen and stored at
 808C for further use. Site directed mutations were intro-
duced using mutagenic primers and the Phusion Flash
High-Fidelity PCR Master Mix (Finnzymes).
The resulting polypeptides were puriﬁed using the same
procedure as for the wild-type protein.
RDs of human MDA5 (residues 897–1025, native
C-terminus) and RIG-I (residues 801–925, native C-termi-
nus) were produced with an N-terminal 6 histidine tag in
E. coli as described for LGP2 RD using a pET28 expres-
sion vector (Novagen). MDA5 and RIG-I RDs were
puriﬁed by immobilized metal aﬃnity, ion exchange chro-
matography and, subsequent to removal of the histidine
tag with thrombin, by gel ﬁltration chromatography. For
SAXS measurements protein samples were concentrated
to 2, 5 and 10 mg/ml, respectively (in 30mM Tris–HCl
pH 7.5, 150mM NaCl, 2mM DTT and 10mM ZnCl2).
Crystallization, crystallographic data collection and
structure determination
LGP2 RD was crystallized using hanging drop vapor dif-
fusion by mixing 2ml of protein solution at 13 mg/ml pro-
tein concentration with 2ml of the reservoir solution
[1.5M (NH4)2SO4, 100mM Tris–HCl pH 8.5]. Crystals
grew after several weeks at 218C. Prior to ﬂash freezing
in liquid nitrogen, the crystals were soaked with 2mM
mercury acetate for 10min and then transferred for
5–10s into the reservoir solution containing 2.5M
(NH4)2SO4. We collected the ﬁnal diﬀraction data to
2.6 A ˚ at ESRF beamline ID 14-4 (European synchrotron
radiation facility, Grenoble, France). Diﬀraction data
were processed with XDS (37). The crystals belong to
space group P212121 and contain four molecules in the
asymmetric unit. The structure was determined by molec-
ular replacement with Phaser (38), using human RIG-I
RD [PDB entry 2QFB, (27)] as a search model. The result-
ing 2Fo-Fc and Fo-Fc electron density allowed initial
manual model building with Coot (39). The model was
iteratively reﬁned by cycles of bulk solvent correction,
overall anisotropic B factor reﬁnement, positional reﬁne-
ment and overall B factor reﬁnement with CNS 1.2 (40)
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removed in the ﬁnal cycles of the reﬁnement, to allow
some structural variations. Manual model building was
performed with Coot and 166 solvent atoms were added
with CNS 1.2. Finally secondary structure was assigned
with DSSP (42). Data collection and model reﬁnement
statistics are summarized in Supplementary Table 1.
RNA preparation
For binding assays, 50-triphosphate containing RNA
was either obtained by in vitro transcription using the
Ambion MEGAshortscript
TM Kit or purchased from
Eurogentec. RNAs from in vitro transcription mixes
were puriﬁed using MicroSpin
TM G-50 columns (GE
Healthcare) and checked for purity by denaturing urea
PAGE. RNAs were ﬂuorescence-labeled by either incor-
porating Alexa Fluor 488-5-UTP during in vitro transcrip-
tion or purchased from IBA with Alexa Fluor 488 as
50-modiﬁcation. Unmodiﬁed oligonucleotides were pur-
chased from Metabion or biomers.net. RNAs used
are listed in Supplementary Table 2.
Fluorescence anisotropy measurements
Fluorescence anisotropy experiments were performed with
a FluoroMax-P ﬂuorimeter (HORIBA Jobin Yvon),
equipped with a Glan-Thompson prism polarizer and con-
nected to a Haake F3 thermostat. Typically, 1ml of buﬀer
(30mM Tris–HCl pH 7.5, 150mM NaCl, 2mM DTT and
10mM ZnCl2) and 37nM RNA (50-Alexa Fluor 488-
-labeled/50-OH dsRNA, 25 bp) were pre-equilibrated in
a quartz cuvette at 128C. Protein samples were added in
a stepwise manner. After mixing and 4min of re-equilibra-
tion, anisotropy data were collected using an excitation
wavelength of 495nm and monitoring the emission at
516nm. The band pass was 5nm for excitation and 5nm
for emission. A maximum number of 10 trials were per-
formed until minimal deviation of the signal was reached.
For the competition assays 800ml of buﬀer, 40nM of an
in vitro transcribed hairpin RNA (Alexa Fluor 488-5-UTP
incorporated, 18bp+4n) and 470nM protein were pre-
equilibrated in a quartz cuvette at 128C. Unlabeled
RNA species (Supplementary Table 2) were added in a
stepwise manner and the drop in anisotropy was moni-
tored after mixing and 4min of re-equilibration.
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) were carried
out in 10% (w/v) acrylamide native gels in Tris borate
buﬀer (10.8g/l Tris, 5.5g/l borate). Samples contained
5% glycerol, 60nM 50 Alexa Fluor 488-labeled/50-OH
dsRNA (25 bp) and diﬀerent concentrations of protein,
diluted from 5mM stock solutions (in 30mM Tris–HCl pH
7.5, 150mM NaCl, 2mM DTT and 10mM ZnCl2).
Samples were incubated for 20min at 48C prior to electro-
phoretic analysis. Gels were analyzed with a Typhoon
TM
scanner (GE Healthcare).
Interferon-breporter assay
HEK293 cells were cultivated in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) (PAA Laboratories) containing
10% fetal calf serum (FCS v/v, Biochrom KG), 1,5mM
L-glutamine (PAA Laboratories) and 8mg/ml ciproﬂoxa-
cin (Bayer Vital GmbH). To measure interferon-b induc-
tion, HEK293 cells were transiently transfected with 40 ng
of a plasmid containing a ﬁreﬂy luciferase reporter gene
under the control of an interferon-b promotor, 40 ng
Renilla reniformis luciferase reporter gene for normaliza-
tion and the indicated amount of expression plasmids
using Genejuice transfection reagent (Novagen). After
24h, cells were stimulated with the indicated RNA oligo-
nucleotide for 18h, as described above. In all experiments,
cell lysates were prepared using passive lysis buﬀer
(Promega) and the reporter gene activity was measured
using ﬁreﬂy luciferase substrate (Biozym) and renilla luci-
ferase substrate (Promega), respectively. Expression levels
of the examined proteins were veriﬁed via western blot
analysis (Supplementary Figure 2).
Small angle X-ray scatteringmeasurements
SAXS data for MDA5 and RIG-I RDs were collected at
DESY beamline X33 (Deutsches Elektronen-Synchrotron,
Hamburg, Germany). Scattering patterns from solutions
of the two constructs at concentrations of 2, 5 and 10 mg/
ml were measured in buﬀer containing 30mM Tris–HCl
pH 7.5, 150mM NaCl, 10mM ZnCl2 and 5mM DTT.
SAXS data were processed, evaluated and models built
applying various programs from the ATSAS 2.1 software
suite (43).
Coordinates and structure factors of LGP2 RD were
deposited at the Protein Data Bank (PDB) with accession
number 2W4R.
RESULTS AND DISCUSSION
Crystallization and structure determination
The expression construct for the RD of human LGP2
was designed using our previously determined crystal
structure of the RD of RIG-I as guide for the domain
boundary. LGP2 RD comprises residues 537–678 (native
C-terminus). The protein was produced in E. coli. After
purifying the protein by ion exchange and gel ﬁltration
chromatography, we were able to crystallize the protein
in space group P212121 with four molecules per asymmet-
ric unit. The crystals diﬀracted to 2.6 A ˚ and we deter-
mined the structure by molecular replacement using the
coordinates for RIG-I RD as search model. The four
copies were initially reﬁned with non-crystallographic
symmetry restraints that were removed during ﬁnal
cycles of reﬁnement. RMSD values for the Ca atoms of
the four molecules in the asymmetric unit have been cal-
culated by LSQMAN (44) with respect to molecule C and
range from 0.6 to 0.7 A ˚ with 117–122 of pairwise matched
residues. A superposition of all four molecules is shown
in Supplementary Figure 1A. Part of the ﬁnal 2FOc-Fc
electron density map is shown in Figure 1B. The ﬁnal
model spans residues 543 to 672, with the loop region
between residues 593 and 601 not visible in the electron
density map. The structure was reﬁned to an R value
of 21.5 (free R=26.6) with good stereochemistry
(Supplementary Table 1).
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The ‘regulatory domain’ RD of LGP2 is a globular,
slightly ﬂattened domain with a concave and convex side
and dimensions of  45 35 30 A ˚ (Figure 1D). It is
organized in three leaves, consisting of two four-stranded
(b1, b2, b9, b10 and b5, b6, b7, b8) and one two-stranded
(b3, b4) antiparallel b-sheet. Small 310 helical turns
(Z1–Z5) connect the three b-sheets. The C-terminus con-
tains a short a-helix (a1). The four-stranded b-sheets are
laterally connected by two protruding loops, each contain-
ing two highly conserved cysteine residues (Cys556 and
Cys559 as well as Cys612 and Cys615). Together, the
four thiol groups of these cysteines coordinate the zinc
ion (or mercury in our crystal structure) in each of the
four molecules in the asymmetric unit (Figure 1D and B).
Comparison of LGP2RD to RIG-I RD
With the exception of some diﬀerences in loop regions that
connect secondary structure, the fold of LGP2 RD is
highly related to the fold of RIG-I RD (Figure 1C). The
RMSD, as calculated by LSQMAN (44), between the Ca
atoms of LGP2 (molecule C) and RIG-I RD is 1.178 A ˚ for
108 matched residues (Supplementary Figure 1B). In par-
ticular, the backbone geometry of the metal coordinating
cluster is, with the exception of one loop insertion in
RIG-I, conserved between RIG-I and LGP2 (Figures 1
and 2A). The metal in LGP2 is coordinated in a tetrahe-
dral manner by the sulfur atoms of the cysteine cluster
C556, C559, C612 and C615. Although we have a mercury
ion in our crystal form we think the geometry is similar
in the presence of zinc, since crystal structures of RIG-I
RD in the presence of mercury and zinc turned out to be
virtually identical (27). W619
LGP2—conserved between
LGP2, RIG-I and MDA5—bounds this cluster towards
the core of the domain. Thus, correct formation of the
metal coordination sphere is presumably necessary
for fold of RDs, which might explain the severe eﬀect of
point mutation in the zinc-binding cluster on activity
of RIG-I (27). In support of this, point mutation in
metal coordinating cysteine residues resulted in an unsta-
ble LGP2 RD, which could not be over-expressed in E.
coli in our hands. A notable diﬀerence in the metal binding
site between RIG-I and LGP2 RD is the loop, which
connects C612
LGP2 and C615
LGP2 (Figure 1C). In RIG-I
this loop is two residues longer, forming a short b-turn.
In MDA5, this loop is one amino acid shorter indicating
that this region could account for functional diﬀerences
between RIG-I-like helicases (Figure 2A).
TheRDofRIG-IwasshowntospeciﬁcallybindtoRNA
with 50-triphosphates and is suggested to be a main sensor
sitefor50-triphosphatecontainingviralRNA. Keyresidues
important for RIG-I RNA binding were mapped to a
groove formed at the interface of the four- and two-
stranded b-sheets. These include several lysines as well as
a histidine, residues which could bind the RNA backbone
and the 50-triphosphate moiety. Intriguingly, two of these
residues, K888
RIG-I and H830
RIG-I are conserved in LGP2
(K626
LGP2 and H579
LGP2, respectively), indicating that
this region could also be an important functional site of
LGP2 (Figure 2A and B). In LGP2 RD, the groove carries
a strong positive electrostatic potential that might be
suitable for RNA backbone interaction (Figure 2B).
Furthermore, the groove is ﬂanked by two conserved 310
turns (Z2 and Z4), which are suitable phosphate recogni-
tion sites (Figure 1D).
However, there are also important structural diﬀerences
among RIG-I and LGP2 RD. K858
RIG-I has been shown
to be essential for 50-triphosphate RNA interactions and
this residue is not conserved in LGP2. In fact, LGP2 pos-
sesses a proline in this position (P606, Figure 2A and B).
Based on these ﬁndings and subsequent mutational ana-
lysis (see subsequently), we propose that the region around
Figure 1. Structure of the RD of human LGP2. (A) Scheme of the
domain arrangement in LGP2 and MDA5. The two N-terminal
CARD motives of MDA5 are depicted in white, the DExH box helicase
domains are shown in gray and the RDs in black. Numbering of the
RDs is according to the constructs used for structural and biochemical
studies. (B) Portion of the ﬁnal 2Fo Fc electron density (1s contour)
at the mercury-binding site superimposed with the ﬁnal model.
(C) Superimposition of ribbon models of LGP2 RD (cyan, black and
yellow) and RIG-I RD (wheat) with highlighted secondary structure
and metal-binding site. Possible RNA binding and speciﬁcity sites are
assigned. (D) Stereo image of a ribbon model of LGP2 RD with high-
lighted and annotated secondary structure, mercury ion (magenta
sphere) and annotated mercury-coordinating cysteines (yellow sticks).
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confer speciﬁcity in RNA binding. In sum, structural com-
parison reveals similarities but also diﬀerences between
LGP2 and RIG-I in regions that were found to be impor-
tant for RIG-I function.
LGP2RD binds to dsRNA ina5’-triphosphate-independent
manner
To learn more about the functional sites of LGP2 RD, we
ﬁrst analyzed whether it can directly bind RNA and what
RNA structures or epitopes might contribute to binding.
The physiological ligand for LGP2 is unknown. Its nega-
tive regulation of RIG-I-dependent signaling in vivo may
result from competition for viral RNA and thus could be
directed against two RIG-I PAMPs, 50-triphosphate RNA
and dsRNA. Since full-length LGP2 has been shown to
bind to dsRNA with a higher preference than ssRNA,
we hypothesized that RD of LGP2 might be one of its
dsRNA recognizing elements. We tested several RNA oli-
gonucleotides (Supplementary Table 2) in equilibrium
binding experiments using ﬂuorescence polarization aniso-
tropy measurements. Indeed, we ﬁnd that LGP2 RD binds
to a dsRNA 25-mer with quite high aﬃnity. We can ﬁt the
binding isotherm with a single site-binding model and
using this model, obtain an apparent Kd of 68 6nM
(Figure 3A).
We then analyzed binding to other RNA structures
using competition experiments (Figure 3B). In these
experiments, a ﬂuorescently labeled dsRNA hairpin is
competed away from LGP2 RD with increasing amounts
of unlabeled ssRNA or dsRNA ligands bearing or lacking
50-triphosphates. Corresponding in length and sequence to
one of the dsRNA strands of the labeled probe, 50-OH
ssRNA is a poor competitor, indicating that LGP2 RD
does not eﬃciently bind to ssRNA. However, 50-OH
dsRNA with blunt ends is a very eﬃcient competitor.
Since dsRNA with two blunt ends binds more eﬃciently
than a 50-triphosphate hairpin of the same length, some
RNA end structures could enhance speciﬁc dsRNA bind-
ing by LGP2 RD.
We next tested whether 50-triphosphates are important
for RNA binding by LGP2 RD (Figure 3B). We tested
both ssRNA and dsRNA carrying a 50-triphosphate. We
did not see a substantial diﬀerence in binding of LGP2
RD to the corresponding RNAs with 50-triphosphate com-
pared to those without. This is in stark contrast to the
50-triphosphate dependence of RNA binding by RIG-I
RD. Taken together, it appears that RD is an important
Figure 2. Structure guided site directed mutagenesis of LGP2 RD. (A) Structure-based sequence alignment of the C-terminal regions of human
LGP2, RIG-I and MDA5. Secondary structure elements corresponding to LGP2 RD are shown above the alignment. Invariant residues are
highlighted with red background, conserved ones in red font. The zinc-coordinating cysteines are marked with asterisks. (B) Localization of
mutations, shown in a cartoon representation with electrostatic surface potential (ranging from blue=5kT/e to red= 5kT/e). The model is
shown in ‘standard view’, used in all other ﬁgures (left) and 1808 rotated around the vertical axis. Mutated residues are highlighted with sticks (cyan).
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50-triphosphates are not central epitopes recognized by
LGP2 RD.
The dsRNA binding site ofLGP2
To identify the RNA binding site of LGP2 RD, we ana-
lyzed the electrostatic surface potential and introduced
point mutations inside and outside of the positive
groove that could form an RNA binding site
(Figure 2B). RNA binding of the mutant RD variants
was analyzed by ﬂuorescence anisotropy (Figure 3A).
Mutations in the convex, positively charged surface
patch in general aﬀect RNA binding, while mutations out-
side these regions did not result in decreased RNA bind-
ing. Most remarkably, K634!E completely abolished
RNA binding. This residue is conserved between RIG-I-
like helicases and situated at the N-terminus of a 310 turn
(Z4) at the center of the concave surface. The equivalent
mutation K888
RIG-I!E also had a severe eﬀect on RIG-I
activity (27). The conservation of this lysine residue in
diﬀerent RDs with evidently diﬀerent RNA speciﬁcities
(50-triphosphate in RIG-I versus dsRNA in LGP2)
argues that this site is not involved in distinguishing dif-
ferent RNA epitopes, but more likely is a central core
RNA interaction site shared by all three RDs.
To our surprise, P606
LGP2!K still bound RNA with
fairly good eﬃciencies, while the equivalent K858
RIG-I!A
severely reduced RNA binding of RIG-I RD and abol-
ished RIG-I activity in vivo. Other mutations in the
same region (H576!Y, W604!A) also bind RNA with
reasonable albeit reduced aﬃnity (Figure 3A).
Interestingly, although Kd values for dsRNA binding by
these mutants are lower than for wild-type RD, we obtain
much higher anisotropy changes compared to the wild-
type RD, indicating that the RNA:protein complexes
formed in the presence of these mutants are larger than
those formed in the presence of wild-type RD. One likely
explanation for this observation is that mutant proteins
can bind to RNA in multimers or can bind simultaneously
at multiple sites, while wild type binds more speciﬁcally to
only one or a few sites.
To test this idea further, we performed EMSAs with
wild-type and mutant LGP2 RDs on dsRNA (Figure 4A
and B). In general, the EMSAs conﬁrm the results of the
anisotropy measurements with respect to altered or
retained dsRNA binding of site directed mutants
(Figure 4A). Concentration-dependent analysis indicates
that wild-type RD indeed shifts dsRNA to deﬁned, spe-
ciﬁc bands. An initial shifted species with higher mobility
is subsequently converted into a species with lower mobil-
ity (Figure 4B). These data suggest that LGP2 RD has two
binding sites on the dsRNA ligand. One possibility is that
RD speciﬁcally forms dimers on a single site on the
dsRNA substrate. Since RD binds to dsRNA better
than a hairpin of the same concentration, another expla-
nation is that perhaps the RNA end structures contribute
to binding and the two EMSA species are corresponding
complexes with one and two RNA ends bound by protein.
Dynamic light scattering, SAXS and analytical gel ﬁltra-
tion suggest that RD is a monomer in the absence of
RNA, and we do not see a convincing protein–protein
dimer interface in the crystal lattice. In the presence of
RNA our anisotropy studies, EMSAs as well as analytical
gel ﬁltration experiments can neither entirely eliminate nor
verify the possibility of dimer formation. This is due to the
resemblance in size between the RNA species and RD.
Furthermore, judging from the dimension of the RD,
more than one molecule could possibly bind to the 18–
25 bp RNA duplexes used (Supplementary Table 2), inde-
pendently of protein–protein interaction. Thus, analysis of
an RNA-induced protein dimer formation must await fur-
ther studies. In any case, we observe very deﬁned species in
Figure 3. Binding of dsRNA to LGP2 RD. (A) Fluorescence aniso-
tropy changes of a 50-Alexa Fluor 488-labeled 25 bp RNA duplex
(37nM) in response to titration with wild-type LGP2 RD (ﬁlled
square, Kd=68 6nM) and various mutants, respectively. Control
mutation N583!D (open diamond, Kd=38 4nM) located on the
convex site of RD and mutation K626!E (open left-facing triangle,
Kd=51 5nM) do not show signiﬁcantly altered dsRNA binding
aﬃnity. Aﬃnities for mutants L621!A (ﬁlled up-facing triangle,
Kd=165 26nM) and K605!E (ﬁlled down-facing triangle,
Kd=140 16nM) are slightly decreased, while a mutation of
K634!E (ﬁlled circle) completely suppresses binding. A decrease of
binding aﬃnity, but increase in maximum reached anisotropy signal
is seen for P606!K (open right-facing triangle, Kd=230 10nM),
W604!A (open square, Kd=136 6nM) and H576!Y (open circle,
Kd=304 10nM). (B) Competition of binding of an Alexa Fluor 488-
5-U-labeled hairpin RNA (in vitro transcriped, 40nM) to LGP2 RD
(470nM) by stepwise addition of diﬀerent non-ﬂuorescent RNA species
(synthetic 50OH/50OH dsRNA: 19 bp; 50PPP/50OH dsRNA: 19 bp;
50OH ssRNA: 19n; 50PPP ssRNA: 19n; and in vitro transcribed
50PPP hairpin: 18 bp 4n) followed by ﬂuorescence anisotropy. Data
points were connected for better outline.
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RD with the dsRNA substrate.
These deﬁned bands are more or less lost when we ana-
lyze H576, W604 and P606 mutants of RD (Figure 4B).
Instead, we observe a more unspeciﬁc distribution
(‘smear’) of even lower mobility complexes. Taking into
consideration that all tested mutants behave like the wild-
type RD during puriﬁcation and no tendency for
enhanced aggregation was observed, our interpretation
of these data is that these mutations do not disrupt
RNA binding per se, but lower the aﬃnity and lead to a
more distributed binding. These mutant RDs could bind
undiscriminatorily to many possible binding sites on the
dsRNA ligand, possibly also as multimers at higher pro-
tein concentrations, which could account for the larger
complexes observed in both EMSA and ﬂuorescence
anisotropy measurements. Taken together, these data
argue that the residues around P606 form a speciﬁcity
site on RD.
Solutionscattering analysis and modeling of MDA5RD
We have not been able to crystallize the RD of MDA5, so
we used small angle X-ray scattering as well as homology
modeling to generate a ﬁrst structural draft of MDA5 RD
(Figure 5). Our construct of MDA5 RD spans residues
897–1025, similar to the used LGP2 and RIG-I RDs.
Small angle X-ray scattering data were collected at
DESY beamline X33 and data processed with programs
from the ATSAS 2.1 suite (43) (Figure 5A). We noticed
some limited aggregation in RIG-I and MDA5 RD sam-
ples at higher concentrations, so very low-resolution data
needed to be truncated. Using GASBORp, we generated
ab initio reconstructions using the dummy residue
approach (Figure 5B). In the case of RIG-I RD, the solu-
tion scattering data correlate well with size and shape of
the respective crystal structures. Likewise, an ab initio
dummy residue model matches the shape and size of the
crystals structure to a high degree.
MDA5 RD produces highly similar scattering data to
RIG-I RD. The resulting ab initio models exhibit a similar
shape and size compared to RIG-I RD and overall match
the geometry of the available RD crystal structures
(Figure 5B). Together with the sequence conservation of
key residues such as core tryptophanes and metal coordi-
nating cysteines (Figure 2), MDA5 RD likely possesses a
similar overall structure as RIG-I and LGP2 RDs. We
generated a homology model of human MDA5 RD with
MODELLER (45) using coordinates of RIG-I and LGP2
RD as base and compared the molecular model to the
solution structure of MDA5 RD. Although the model
will presumably diﬀer in the precise side chain and loop
geometries from an experimental structure of MDA5 RD,
several important conclusions can be drawn at this stage,
including analysis of the surface potential. Indeed, the
concave surface, identiﬁed in RIG-I and LGP2 RDs as
important RNA recognition site, also carries a highly pos-
itive electrostatic potential in MDA5 RD (Figure 5C).
In addition, a lysine residue, K984
MDA5, is situated at
the same position as K888
RIG-I and K634
LGP2, both of
which are key elements of RNA binding by RIG-I and
LGP2 RDs, respectively. In contrast, MDA5 possesses
an isoleucine in the place of P606
LGP2 or K858
RIG-I, and
the proposed ‘speciﬁcity site’ diﬀers in all three RDs.
Taken together, MDA5 RD could share with RIG-I and
LGP2 RD a common RNA binding site at Z4, although
the nature of the PAMP sensed by MDA5 and perhaps
MDA5 RD remains to be identiﬁed.
Effect of LGP2DExH domainand RD in modulating
RIG-I- andMDA5-dependent signaling
To elucidate the mechanisms by which LGP2 diﬀerentially
regulates RIG-I and MDA-5 and the role of its RD in
these processes, we expressed increasing amounts of
LGP2 together with RIG-I or MDA5 in Hek293 cells
and monitored activation of an interferon-b reporter
system after stimulation with the appropriate ligand
(Figure 6). As expected, when we co-expressed LGP2
together with RIG-I, loss of interferon-promoter activa-
tion was observed proportional to the level of LGP2 over-
expression, consistent with previously reported data
(14,35). This suggests a competitive mechanism at the
level of the ligand or at the level of downstream signaling
Figure 4. Electrophoretic mobility shift assays of LGP2 RD and mutants with dsRNA. (A) Retardation of 50-Alexa Fluor 488-labeled dsRNA (25bp,
60nM) in a 10% native polyacrylamide gel after incubation with 400nM wild-type (wt) LGP2 RD or indicated RD mutants, respectively.
(B) Retardation of 50-Alexa Fluor 488-labeled dsRNA (25bp, 60nM) in a 10% native polyacrylamide gel after incubation with increasing concen-
trations (0, 0.4, 0.8, 1.6, 3.2 and 6.4 mM) of wt LGP2 RD and mutants P606!K, W604!A and H576!Y. For the wild-type RD two distinct bands
appear shifted compared to free dsRNA at low protein concentrations already. The mutants show unspeciﬁc shifting and lower aﬃnity to the RNA,
indicated by remaining free dsRNA bands for all protein concentrations.
2020 Nucleic Acids Research, 2009, Vol. 37,No. 6molecules as it has already been proposed (15).
Interestingly, when we co-expressed MDA5 with diﬀerent
amounts of LGP2 protein in the presence of the dsRNA
analog poly(I:C), we found that optimal activation was
observed at LGP2 expression levels similar to those of
MDA5. This balance-type behavior suggests that the
mechanism of MDA5 activation by LGP2 is mechanisti-
cally diﬀerent and might involve the formation of a
deﬁned hetero-complex that contains the ligand, which
is supported by our ﬁnding that the LGP2 RD similar
to MDA5 binds dsRNA.
To clarify the relative contributions of the two LGP2
functional domains, we examined RIG-I repression and
MDA5 activation in the presence of diﬀerent amounts of
either full-length LGP2 or one of the two functional
domains, DExH box domain (NT) or RD. Expression
levels for all constructs were shown to be regular when
analyzed by western blots (Supplementary Figure 2A
and B). Similar to what has been observed before,
we ﬁnd that the LGP2 RD domain is able to mediate
RIG-I repression albeit weaker than the full-length (46).
Consistently, we do observe a contribution of the
DExH box to LGP2-mediated repression of RIG-I,
which would be in line with a model in which the helicase
domain is also involved in competitive binding to either the
RIG-I ligand or downstream signaling molecules. Instead,
analysis of LGP2-mediated MDA5 activation showed that
full-length LGP2 activated MDA5 as expected and no
activation could be observed expressing diﬀerent amounts
ofeither LGP2 DExH or regulatory domain. This indicates
that neither the LGP2 DExH domain nor the LGP2 RD
alone are suﬃcient to mediate the synergistic eﬀect on
MDA5 activation and that this might involve more com-
plex protein–protein and protein–ligand interactions.
To examine the importance of the zinc-binding motif
for LGP2’s function in repressing RIG-I signaling or
synergizing with MDA5, we co-expressed wild-type
LGP2 or a mutant lacking one of the conserved cysteines
(C615A) in the motif together with RIG-I or MDA5. The
respective expression levels in human cells were analyzed
in western blots (Supplementary Figure 2C), showing sim-
ilar protein levels for the C615A mutant compared to the
wild-type proteins. When we analyzed LGP2-mediated
repression of RIG-I signaling in Sendai virus infected
cells, a partial loss-of-function phenotype for LGP2
C615A was observed, which ﬁts well with our ﬁnding
that both the RD and the DExH domain contribute to
RIG-I repression. Interestingly, when we analyzed MDA5
activation by LGP2 the loss-of-function phenotype was
nearly complete, indicating that the integrity of the
LGP2 RD is essential for full MDA5 function.
CONCLUSIONS
We established that although the RD of LGP2 has a struc-
ture related to the RD of RIG-I, it exhibits remarkably
Figure 5. Comparison of RDs of RIG-I-like helicases. (A) Small angle X-ray scattering curves of RIG-I RD and MDA5 RD (upper panel, merged
from curves obtained with protein concentrations of 2, 5 and 10 mg/ml). The lower panel shows the pair distribution functions for RIG-I RD and
MDA5 RD derived from raw data with Gnome (ATSAS 2.1). (B) Superimposition of SAXS surface models of RIG-I (left) and MDA5 RD (right)
with crystal structures of RIG-I RD (yellow, brown) and a model of MDA5 RD (model based on RIG-I and LGP2 RD crystal structure, blue, light
blue), respectively. (C) Electrostatic surface potential (ranging from blue=9 kT/e to red= 9 kT/e) of LGP2 RD, RIG-I RD (from crystal structure)
and a model of MDA5 RD. Residues crucial for general RNA interaction and either 50-triphosphate RNA speciﬁcity in RIG-I (K888, buried K858)
or dsRNA speciﬁcity in LGP2 (corresponding K634, P606 and additionally buried W604 and K605) are highlighted as well as corresponding residues
for MDA5 RD (K983, buried I956).
Nucleic Acids Research,2009, Vol.37, No. 6 2021diﬀerent RNA binding speciﬁcities. Thus, our results
suggest that RDs of RIG-I-like helicases confer pattern
speciﬁcity. LGP2 RD speciﬁcally binds dsRNA in a 50-
triphosphate-independent manner, perhaps recognizing
also some dsRNA end structures. The binding aﬃnity of
LGP2 RD to RNA duplexes is similar or even higher than
the aﬃnity of RIG-I RD for 50-triphosphate RNA, indi-
cating a physiologically relevant interaction. We have
not found an increased interaction in the presence of
50-monophosphates (data not shown), and conclude that
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Figure 6. LGP2 represses RIG-I and activates MDA5 by diﬀerent mechanisms. (A) Hek293 cells were transfected with plasmids coding for RIG-I-
HA (10ng plasmid), diﬀerent amounts of LGP2-HA (2, 5, 10 and 50ng plasmid) and plasmids encoding for a luciferase-based interferon-b reporter
assay system. After 24h, transfected cells were stimulated using 50-triphosphate RNA or left unstimulated as a control. Relative luciferase activities
were determined 18h after stimulation. The values indicated are normalized to an unstimulated control that expresses only the assay system
components (mock). (B) Hek293 cells were transfected with plasmids coding for MDA5-HA (1ng plasmid) and diﬀerent amounts of LGP2-HA
(0.05, 0.1, 1, 5, 50 and 100ng plasmid) and stimulated with poly(I:C) 24h after transfection. Luciferase activities were measured und are represented
as in (A). (C) Hek293 cells were transfected with RIG-I-HA and diﬀerent amounts of wild-type (wt), amino-terminal (NT, amino acids 1–468) or
carboxy-terminal (RD, amino acids 476–678) constructs of LGP2-HA and assayed for interferon-b reporter activity. (D) Hek293 cells were trans-
fected with MDA5-HA and diﬀerent amounts of wild-type (wt), amino-terminal (NT, amino acids 1–468) or carboxy-terminal (RD, amino acids
476–678) constructs of LGP2-HA and assayed for interferon-b reporter activity. (E) Hek293 cells were assayed for suppression of RIG-I signaling by
wild-type LGP2 or a C615A mutant of LGP2 (10ng and 100ng) as in (A) using Sendai virus (SeV) infection as a stimulus. (F) Hek293 cells were
assayed for activation of MDA5 signaling by wild-type LGP2 or a C615A mutant of LGP2 as in (B).
2022 Nucleic Acids Research, 2009, Vol. 37,No. 6LGP2 speciﬁcally senses duplex RNA. We see high bind-
ing aﬃnities for both 25 bp and 19 bp duplexes (Figure 3A
and B), which are sequence unrelated. It is therefore unli-
kely that the RNA sequence is critical for binding by
LGP2 RD. However, we do not want to rule out that
perhaps some aspects of RNA sequence, structure or
length signiﬁcantly inﬂuences binding aﬃnity and it will
be necessary to address these points in future studies.
The function and mechanism of LGP2 in antiviral
innate immune response is puzzling because recent analy-
sis of LGP2 deﬁcient mice has uncovered a surprising
dichotomy of LGP2 function with respect to regulation
of RIG-I and MDA5 activity. Whereas LGP2-deﬁcient
mice showed reduced susceptibility to viruses recognized
by RIG-I, these mice show enhanced susceptibility to chal-
lenge with MDA5-speciﬁc viruses like EMCV (35).
Complex formation between LGP2 and these receptors
might account for some of these activities. For instance,
a complex of a functional LGP2 with MDA5 could spe-
ciﬁcally detect longer dsRNA stretches, explaining why a
fully functional and intact LGP2 is necessary to augment
polyI:C-dependent MDA5 signaling, whereas isolated
DExH domain and RD have no eﬀect on
MDA5-dependent signaling. In contrast, inhibition of
RIG-I-dependent signaling does not require an intact
LGP2, but is also observed for the individual DExH
domain and RD. Part of this inhibition could involve pro-
tein–protein interactions (15). However, we have not been
able to detect any protein–protein interactions of LGP2
RD with RIG-I so far, so a plausible explanation for the
inhibitory eﬀect of RD is that due to its strong dsRNA
binding it can compete with RIG-I for dsRNA. RIG-I can
sense diﬀerent viral RNA patterns, including RNA duplex
regions as well as 50-triphosphate moieties on RNA. Our
results of the 50-triphosphate-independent interaction of
LGP2 RD with RNA make it unlikely that LGP2 com-
petes with RIG-I for 50-triphosphate RNA. Rather, our
results suggest that LGP2 RD could compete with RIG-I
for RNA duplex regions, another eﬃcient activator of
RIG-I, which presumably binds at the dsRNA-activated
DExH box domain. Since duplex regions are abundant in
many cellular RNA species, LGP2 might help to prevent
false positive signaling of non-viral dsRNA by RIG-I,
but could help to detect dsRNA by MDA5. A model of
the competitive and augmentative role of LGP2 is shown
in Figure 7.
Our data suggest that RDs of all three RIG-I-like heli-
cases are RNA binding elements with a common core
RNA binding site but speciﬁc adaptation to their speciﬁc
patterns. In general, the binding site corresponds well with
NMR titration experiments on RIG-I RD (25). We pro-
pose that the speciﬁcity loop is involved in the diﬀerential
sensing of RNA ligands. The pattern for MDA5 and its
RD needs to be identiﬁed, but positive augmentation by
LGP2 with its dsRNA binding activity suggests that RNA
duplexes play a role in MDA5-dependent signaling, con-
sistent with recent in vivo data on MDA5-dependent sen-
sing of long RNA duplexes (47). In this regard, our results
establish a framework for the detailed analysis of RNA
selectivity by regulatory domains of RIG-I-like helicases.
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